Robillard, Rébecca
Carpenter, Joanne S.
Rogers, Naomi L.
Fares, Sarah
Grierson, Ashlee B.
Hermens, Daniel F.
Naismith, Sharon L.
Mullin, Sharon J.
Feilds, Kristy-Lee
Glozier, Nick
Scott, Elizabeth M.
Hickie, Ian B.
Article History
Received: 7 May 2017
Revised: 5 August 2018
Accepted: 9 August 2018
First Online: 9 October 2018
Competing interests
: D.F.H. has received honoraria for educational seminars from Janssen-Cilag and Eli Lilly. E.M.S. is the (unpaid) Clinical Director of Headspace Services at the BMC, the (unpaid) Coordinator of the Youth Mental Health Research Programme at the BMC, and Deputy Director of St. Vincent’s Private Hospital Young Adult Mental Health Unit. E.M.S. has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. I.B.H. has led depression and other mental health research projects that have been supported by a variety of pharmaceutical partners. Investigator‐initiated studies have been supported by Servier and Pfizer. He has received honoraria for his contributions to professional educational seminars supported by the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). The remaining authors declare that they have no conflict of interest.